Jacek Olczak, Philip Morris CEO (Yen Meng Jiin/Singapore Press via AP Images)
July 9, 2021 06:50 AM EDT
Deals

Kick­ing the habit, Philip Mor­ris forges $1.5B deal to ac­quire Vec­tura in race to build a top in­haled-drug com­pa­ny

John Carroll

Editor & Founder

Philip Mor­ris is switch­ing fo­cus from smok­ing to health in a big way. And to­day it’s trum­pet­ing a move in­to in­haled ther­a­peu­tics with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times